Themis Bioscience’s Chikungunya Vaccine Study Results Published

This article is over 11 years old

Published the 1 March 2015 Updated 14 October 2016

Phase 1 trial of the vaccine candidate which was developed under an R&D collaboration between Themis Bioscience GmbH and the Institut Pasteur (Paris) shows good immunogenicity, safety and tolerability.